MatthewSmithMDPhD

Oncology • Boston, MA

Genitourinary Oncology, Hematologic Oncology

Director, MGH Genitourinary Malignancies Program

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Smith's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-724-5257

Fax+1 617-726-4899

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1994
Duke University School of MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1994 - 2025
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 2
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy Start of enrollment: 2006 Mar 01
Completed
Phase 3
Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2002 Nov 01
Completed
Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer Start of enrollment: 2006 Aug 01
Completed
Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors Start of enrollment: 2007 Sep 01
Completed
Phase 2
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 1
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Start of enrollment: 2018 Nov 26
Active, not recruiting
Phase 2, Phase 3
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2021 Jan 20
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

7 citations
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patient...
Fred Saad, Maha H A Hussain, Bertrand Tombal, Karim Fizazi, Cora N Sternberg
European Urology. 2024-10-01
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MA...
Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, Eleni Efstathiou, Gerhardt Attard
European Urology. 2024-09-23
2 citations
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis.
Fabio Turco, Silke Gillessen, Giorgio Treglia, Karim Fizazi, Matthew R Smith
Prostate Cancer and Prostatic Diseases. 2024-09-01

Other

Initial hormone therapy for metastatic prostate cancer
Smith MR, Lee RJ
http://www.uptodate.com/contents/initial-hormone-therapy-for-metastatic-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09
Side effects of androgen deprivation therapy
Smith MR, Crawford ED
http://www.uptodate.com/contents/side-effects-of-androgen-deprivation-therapy
UpToDate, Wolters Kluwer Health - 2013-03-27

Press Mentions

Darolutamide Ups Survival in Metastatic Hormone-Sensitive Prostate CancerFebruary 17th, 2022
Another PARP Inhibitor Active in BRCA-Mutant Prostate CancerFebruary 8th, 2022
Accelerating Precision Medicine in Metastatic Prostate CancerNovember 17th, 2020
Join now to see all